Chloroquine and Dapsone Topical Interaction

Understanding the Chloroquine and Dapsone Topical Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Chloroquine belongs to the Antimalarial class and Dapsone Topical belongs to the Topical Anti-Inflammatory class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: Both of these drugs can interfere with the way your red blood cells deliver oxygen to your body. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Chloroquine has 5 total documented interactions on file in this dataset, and Dapsone Topical has 10. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Talk to your healthcare provider about the risks and watch for any unusual tiredness or trouble breathing. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Chloroquine or Dapsone Topical based on a web page, speak with your prescriber or pharmacist before making any change.